TY - JOUR
T1 - Nanocarrier-Based Targeted Therapies for Myocardial Infarction
AU - George, Thomashire Anita
AU - Hsu, Chuan-Chih
AU - Meeson, Annette
AU - Lundy, David J.
N1 - Funding Information:
This work was funded by the Ministry of Science and Technology (MOST) Taiwan, grant number 109-2636-B-038-003. Thomashire Anita George is supported by the Schlumberger Faculty for the Future Program.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/25
Y1 - 2022/4/25
N2 - Myocardial infarction is a major cause of morbidity and mortality worldwide. Due to poor inherent regeneration of the adult mammalian myocardium and challenges with effective drug delivery, there has been little progress in regenerative therapies. Nanocarriers, including liposomes, nanoparticles, and exosomes, offer many potential advantages for the therapy of myocardial infarction, including improved delivery, retention, and prolonged activity of therapeutics. However, there are many challenges that have prevented the widespread clinical use of these technologies. This review aims to summarize significant principles and developments in the field, with a focus on nanocarriers using ligand-based or cell mimicry-based targeting. Lastly, a discussion of limitations and potential future direction is provided.
AB - Myocardial infarction is a major cause of morbidity and mortality worldwide. Due to poor inherent regeneration of the adult mammalian myocardium and challenges with effective drug delivery, there has been little progress in regenerative therapies. Nanocarriers, including liposomes, nanoparticles, and exosomes, offer many potential advantages for the therapy of myocardial infarction, including improved delivery, retention, and prolonged activity of therapeutics. However, there are many challenges that have prevented the widespread clinical use of these technologies. This review aims to summarize significant principles and developments in the field, with a focus on nanocarriers using ligand-based or cell mimicry-based targeting. Lastly, a discussion of limitations and potential future direction is provided.
KW - exosome
KW - ischemia
KW - liposome
KW - myocardial infarction
KW - nanoparticle
UR - http://www.scopus.com/inward/record.url?scp=85129670747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129670747&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14050930
DO - 10.3390/pharmaceutics14050930
M3 - Review article
C2 - 35631516
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 5
M1 - 930
ER -